Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center phase II study of erlotinib in patients with metastatic
or locally advanced, unresectable pancreatic cancer who have received up to one line of
gemcitabine based chemotherapy.